Evidence-based value and access strategies

Solutions: Overview

The commercial success of an innovation will be determined not only by its clinical profile, but also its value to the individual, institution, or health system that will pay for the product or service. Compass offers a comprehensive menu of solutions for each phase of development, to optimize the price and reimbursement in US and global markets.


Projects by life cycle stage

  • At Compass, we conduct assessments and strategies for products in all stages of development and commercialization, from pre-clinical to FDA approved and marketed products
  • Most recent projects involved strategies for assessing and optimizing the value of a pipeline asset…usually in Phase II

Compass website content and screenshots_02-09-16

Therapy AreasTherapeutic areas

Compass’ recent projects reflect expertise in a broad range of therapeutic categories, territories, evolving care settings, and orphan diseases.

Our focus at Compass is on life science market access with broad therapeutic experience:

  • 93% of deliverables included pricing and reimbursement assessments and strategies
  • 56% of projects were for pipeline assets, usually in late Phase II, including therapeutic landscapes and clinical development strategies
  • 28% involved assessments of licensing, acquisition, or partnering opportunities
  • 20% assessed orphan indications

Compass has extensive US and EU experience in orphan diseases and understanding of the decision making for price and access. In 2012-2015, Compass delivered market access assessments and strategies for these orphan diseases; majority were US and EU assessments with payers and KOLs.

CV / metabolic

  • Familial hypercholesterolemia
  • Chronic thromboembolic pulmonary hypertension (CTEPH)


  • Hyperhidrosis
  • Dermatomyositis
  • Epidermolysis bullosa

Growth disorders

  • Acromegaly
  • Achondroplasia
  • Sporadic inclusion body myositis
  • Urea cyclic disorder


  • Hemophilia
  • Sickle cell anemia / beta thalassemia
  • Paroxysmal nocturnal hemoglobinuria
  • Thrombotic thrombocytopenic purpura

Infectious diseases

  • Necrotizing soft tissue infections


  • Fabry disease
  • Huntington’s disease
  • Mucopolysaccharidosis Type IIIA
  • Parkinson’s disease


  • Acute myeloid leukemia
  • Hepatocellular carcinoma
  • Multiple myeloma
  • Malignant melanoma
  • Glioblastoma multiforme


  • Retinopathy of prematurity
  • Retinitis pigmentosa
  • Leber congenital amaurosis (LCA)
  • Neuromyelitis optica

Other orphan indications

  • Achalasia
  • Lambert-Eaton myasthenic syndrome


  • Cystic fibrosis
  • Pulmonary arterial hypertension and idiopathic pulmonary fibrosis
  • Bronchopulmonary dysplasia


  • IgA nephropathy
  • Transplant related orphan indications
  • Treatment in HSCT
  • Bronchiolitis obliterans syndrome
  • CMV in transplant patients

Types of clients
Industry sectors we service include:

  • Pharmaceutical
  • Biotech
  • Medical device and diagnostic
  • Ex-US pharma/biotech
  • Emerging life science
  • Venture funds
Global experience

Compass has conducted primary research with KOLs and payers in sixteen different countries using our extensive network of local consultants. We partner with and work closely with our ex-US consultants who not only conduct interviews in the local language but provide experience and expertise on their market.